Department of Cardiac Surgery, Vanderbilt University, Nashville, TN 37205, USA.
Eur J Cardiothorac Surg. 2013 Sep;44(3):472-6; discussion 476-7. doi: 10.1093/ejcts/ezt077. Epub 2013 Mar 20.
Repair of either the mitral (M) or tricuspid (T) valve in single valve surgery is associated with reduced operative mortality. It is unclear, however, how valve repair influences mortality in combined MT procedures. This topic was evaluated in the Society of Thoracic Surgeons database.
From 1993 through 2007, 21 056 patients underwent concomitant MT valve surgery. Group I had M&T replacement (n = 1130), Group II had M repair and T replacement (n = 216), Group III had M replacement and T repair (n = 11 448) and Group IV had both M&T repair (n = 8262). Unadjusted operative mortalities (UOMs) and morbidities of Groups I-IV were assessed, and logistic regression analysis adjusted for differences in baseline patient profiles. Surgical outcomes were expressed as UOMs, and also adjusted odds ratios (ORs) for mortality.
Group IV was older with more coronary artery bypass grafting and generally less comorbidity, and Group I had more endocarditis, mitral stenosis and reoperation. UOM values were: Group I = 16.8, Group II = 10.2, Group III = 10.3 and Group IV = 8.0%. In the multivariable model, factors influencing mortality included: age (per 5-year increase, OR = 1.15), renal failure with dialysis (OR = 3.22), emergency status (OR = 3.14), second or more reoperations (OR = 1.92) and later surgical date (OR = 0.63). Both M and T repair were independently associated with lower operative mortalities vs prosthetic valve replacement (OR = 0.83 and 0.60, respectively, P < 0.003).
In MT double valve surgery, repair of either valve is associated with lower risk-adjusted mortality when compared with replacement and, when feasible, multiple valve repair should be considered the optimal treatment. Within the limitations of observational analysis, these data support continued efforts to increase M&T repair rates.
在单一瓣膜手术中修复二尖瓣(M)或三尖瓣(T)与降低手术死亡率相关。然而,在联合 MT 手术中,瓣膜修复如何影响死亡率尚不清楚。本研究课题在胸外科医师学会数据库中进行了评估。
1993 年至 2007 年间,21056 例患者接受了同时行 MT 瓣膜手术。I 组患者行 M&T 置换术(n=1130),II 组患者行 M 修复术和 T 置换术(n=216),III 组患者行 M 置换术和 T 修复术(n=11448),IV 组患者行 M&T 修复术(n=8262)。评估了 I-IV 组的未调整手术死亡率(UOM)和发病率,并对基线患者特征的差异进行了逻辑回归分析。手术结果表示为 UOM,并对死亡率进行了调整比值比(OR)。
IV 组患者年龄较大,行冠状动脉旁路移植术的比例较高,且一般合并症较少,而 I 组患者的感染性心内膜炎、二尖瓣狭窄和再次手术的比例较高。UOM 值分别为:I 组=16.8%、II 组=10.2%、III 组=10.3%和 IV 组=8.0%。在多变量模型中,影响死亡率的因素包括:年龄(每增加 5 岁,OR=1.15)、肾衰竭伴透析(OR=3.22)、紧急状态(OR=3.14)、二次或多次再次手术(OR=1.92)和较晚的手术日期(OR=0.63)。M 和 T 修复与人工瓣膜置换术相比,均与较低的手术死亡率独立相关(OR=0.83 和 0.60,均 P<0.003)。
在 MT 双瓣膜手术中,与置换术相比,修复任何一个瓣膜都与较低的风险调整死亡率相关,并且在可行的情况下,应考虑行多瓣膜修复术作为最佳治疗方法。在观察性分析的局限性内,这些数据支持继续努力提高 M&T 修复率。